Details of the Drug Pharmacogenomic Perturbation Atlas

Cefotetan Drug Info

Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid

Therapeutic Class

Antibiotics

Cross-matching ID

PubChem CID

53025

ChEBI ID

CHEMBL3499

CAS Number

CAS 69712-56-7

TTD Drug ID

D0AP9T

VARIDT Drug ID

DR01386

General Information of Drug (ID: DM07TX3)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
PPAR signaling pathway	1.68	2.99e-1	66/74 (89.19%)	PPARG;PLIN2;HMGCS1;...
Mineral absorption	1.62	2.99e-1	48/60 (80%)	MT1X;MT1M;MT1H;...
Spliceosome	1.56	3.56e-1	101/150 (67.33%)	HSPA1A;SNRPD1;HSPA6;...
Sulfur relay system	1.49	4.95e-1	5/8 (62.5%)	MOCS2;TST;NFS1
Terpenoid backbone biosynthesis	1.46	5.10e-1	18/22 (81.82%)	HMGCS1;ICMT;MVD;...
Cholesterol metabolism	1.45	4.68e-1	44/50 (88%)	LPL;STAR;VDAC1;...
Butanoate metabolism	1.45	4.03e-1	23/28 (82.14%)	ALDH5A1;HMGCS1;ABAT;...
Fatty acid degradation	1.45	3.55e-1	40/43 (93.02%)	ACADVL;ECHS1;ACSL3;...
Hematopoietic cell lineage	1.44	3.37e-1	90/99 (90.91%)	CR2;CD59;ANPEP;...
Ascorbate and aldarate metabolism	1.41	3.76e-1	15/30 (50%)	UGDH;UGT2B4;UGT2B28;...
Bile secretion	1.41	3.48e-1	68/90 (75.56%)	CA2;KCNN2;SLC4A4;...
Homologous recombination	1.40	3.27e-1	35/41 (85.37%)	BRIP1;NBN;BABAM1;...
Breast cancer	1.40	3.08e-1	119/147 (80.95%)	HEY1;FOS;TCF7L1;...
Valine, leucine and isoleucine degradation	1.39	3.00e-1	42/48 (87.5%)	DLD;HMGCS1;ABAT;...
Propanoate metabolism	1.39	2.91e-1	30/34 (88.24%)	DLD;SUCLG2;ABAT;...
Complement and coagulation cascades	1.37	3.10e-1	76/85 (89.41%)	C7;CR2;CD59;...
Proximal tubule bicarbonate reclamation	1.37	2.95e-1	21/23 (91.3%)	CA2;SLC4A4;ATP1B2;...
Systemic lupus erythematosus	1.33	3.66e-1	45/135 (33.33%)	C7;SNRPD1;C3;...
Cell cycle	1.32	3.64e-1	110/124 (88.71%)	CDC20;SMC1A;PLK1;...
Thyroid cancer	1.31	3.85e-1	36/37 (97.3%)	CDH1;PPARG;TCF7L1;...
Antigen processing and presentation	1.29	4.22e-1	60/78 (76.92%)	HSPA1A;CALR;HSPA6;...
One carbon pool by folate	1.26	4.63e-1	15/20 (75%)	MTHFD2L;MTHFD1;DHFR;...
DNA replication	1.22	5.58e-1	34/36 (94.44%)	DNA2;LIG1;POLA2;...
Primary bile acid biosynthesis	1.21	5.54e-1	15/17 (88.24%)	CH25H;ACOX2;SLC27A5;...
Non-homologous end-joining	1.21	5.55e-1	11/13 (84.62%)	XRCC5;DNTT;LIG4;...
RNA transport	1.20	5.67e-1	128/186 (68.82%)	PNN;POP5;SEH1L;...
Pyrimidine metabolism	1.20	5.53e-1	40/56 (71.43%)	DCK;DPYS;DHODH;...
Pentose and glucuronate interconversions	1.19	5.46e-1	17/34 (50%)	UGDH;RPE;UGT2B4;...
Protein processing in endoplasmic reticulum	1.19	5.42e-1	127/171 (74.27%)	HSPA1A;PDIA6;DNAJA1;...
mRNA surveillance pathway	1.16	5.67e-1	71/98 (72.45%)	PNN;MAGOHB;FUS;...
cAMP signaling pathway	-1.45	2.14e-1	188/216 (87.04%)	ADCY3;RYR2;HTR4;...
Circadian entrainment	-1.45	2.16e-1	85/97 (87.63%)	GNG4;CACNA1I;KCNJ3;...
Bladder cancer	-1.45	2.21e-1	40/41 (97.56%)	CCND1;DAPK1;CDKN1A;...
Glutamatergic synapse	-1.46	2.26e-1	97/114 (85.09%)	ADCY9;GNAS;GNAO1;...
Inflammatory bowel disease	-1.47	2.18e-1	58/65 (89.23%)	TLR5;TGFB2;SMAD3;...
Morphine addiction	-1.47	2.26e-1	80/91 (87.91%)	GABRA6;PRKACG;PDE1C;...
Hypertrophic cardiomyopathy	-1.48	2.12e-1	81/90 (90%)	EMD;RYR2;SLC8A2;...
C-type lectin receptor signaling pathway	-1.49	2.11e-1	93/104 (89.42%)	JUN;MAPK9;NFATC1;...
Long-term potentiation	-1.53	1.64e-1	61/67 (91.04%)	CALML5;PPP3CB;RAP1B;...
Staphylococcus aureus infection	-1.55	1.39e-1	72/95 (75.79%)	KRT9;KRT14;KRT33B;...
Cocaine addiction	-1.56	1.37e-1	42/49 (85.71%)	TH;JUN;ATF4;...
Oxytocin signaling pathway	-1.56	1.41e-1	128/154 (83.12%)	KCNJ3;ADCY3;RYR2;...
Necroptosis	-1.57	1.36e-1	113/159 (71.07%)	MAPK9;CHMP6;STAT4;...
Selenocompound metabolism	-1.58	1.41e-1	11/17 (64.71%)	CTH;PAPSS1
Protein digestion and absorption	-1.60	1.24e-1	78/103 (75.73%)	ELN;ATP1A2;FXYD2;...
Vascular smooth muscle contraction	-1.60	1.31e-1	113/133 (84.96%)	PLA2G6;PLA2G4A;RAMP1;...
Focal adhesion	-1.61	1.32e-1	180/201 (89.55%)	ITGB7;PXN;ITGB4;...
GABAergic synapse	-1.61	1.36e-1	76/89 (85.39%)	GABRE;GABRB1;GNG10;...
Renin secretion	-1.62	1.39e-1	61/69 (88.41%)	NPR1;CLCA4;CREB1;...
Long-term depression	-1.63	1.39e-1	55/60 (91.67%)	LYN;PLA2G4A;ITPR3;...
ECM-receptor interaction	-1.63	1.50e-1	80/88 (90.91%)	ITGB7;ITGB4;GP9;...
Ferroptosis	-1.63	1.67e-1	36/41 (87.8%)	STEAP3;GCLC;PCBP2;...
D-Glutamine and D-glutamate metabolism	-1.63	1.83e-1	5/5 (100%)	GLS;GLUD2;GLUD1
Mitophagy	-1.66	1.60e-1	56/68 (82.35%)	CSNK2A1;BCL2L13;MFN1;...
Dilated cardiomyopathy	-1.67	1.77e-1	86/96 (89.58%)	ADCY3;EMD;RYR2;...
Proteoglycans in cancer	-1.74	9.27e-2	172/205 (83.9%)	FLNC;PTK2;SLC9A1;...
Arachidonic acid metabolism	-1.78	7.93e-2	48/61 (78.69%)	PTGS2;LTA4H;PTGDS;...
Mucin type O-glycan biosynthesis	-1.81	6.91e-2	20/36 (55.56%)	ST3GAL2;C1GALT1C1;B3GNT3;...
Gap junction	-1.83	8.54e-2	72/88 (81.82%)	GUCY1B1;PRKCB;LPAR1;...
Salivary secretion	-1.85	1.46e-1	76/93 (81.72%)	CST3;CST2;KCNN4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 2.22uM	24H